DTx Pharma names new vice president, Biology
29 July 2020 -

DTx Pharma Inc, a United States-based company that develops technology for delivery of RNA medicines, has named Bryan Laffitte, PhD as its new vice president, Biology, it was reported on Tuesday.

In the new role, Dr Laffitte will manage the company's research and development team and look for new target opportunities for the company's fatty acid delivery platform.

Dr Laffitte has around twenty years of pharmaceutical and biotechnology industry experience. Prior to joining DTx Pharma Inc, he served Inception Therapeutics Inc as vice president, Biology. He also served in roles of increasing responsibility for more than 13 years at the Genomics Institute of the Novartis Research Foundation, Novartis Institutes of Biomedical Research.

He was also a member of the Novartis FXR Agonist global project team and acted as co-lead of the strategic initiative on targeted drug delivery.